{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:01:44Z","timestamp":1784646104586,"version":"3.55.0"},"reference-count":28,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) has been reported in association with hypercalcitoninemia, but the calcitonin (Ct) values to expect in CKD patients are unknown. This study aimed to evaluate Ct levels in CKD patients using an accurate chemiluminescent immunoassay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two population datasets were analyzed: Group 1 consisted of 9,450 anonymous subjects with Ct and creatinine measurements; this group was subdivided according to eGFR into a control series (eGFR \u2265 90 mL\/min\/1.73 m2, n = 4,294) and a CKD series (eGFR &amp;lt; 90 mL\/min\/1.73 m2, n = 4,022). Group 2 consisted of 135 patients with CKD (78.5% in stage 5). Renal function and Ct levels were retrospectively evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Group 1 CKD series had a median Ct of 1.0 ng\/L (IQR: 1.0\u20132.8 ng\/L), 181 patients (4.5%) had Ct &amp;gt; 10 ng\/L and \u226430 ng\/L, and 35 patients (0.9%) had Ct \u2265 30 ng\/L. Median Ct differed significantly according to CKD stage: 1.00 ng\/L (IQR: 1.00\u20132.40 ng\/L) in stage 2; 1.20 ng\/L (IQR: 1.00\u20134.30 ng\/L) in stage 3; 2.80 ng\/L (IQR: 1.00\u20136.75 ng\/L) in stage 4; and 4.55 ng\/L (IQR: 1.00\u201311.30 ng\/L) in stage 5 (P &amp;lt; 0.001). Median Ct in the control series was 1.0 ng\/L (IQR: 1.0\u20132.9 ng\/L). Ct levels &amp;gt;10 ng\/L were significantly associated with CKD stage and were observed in 16.7% of stage 4 patients and 31.1% of stage 5 patients vs 4.3% of controls (P &amp;lt; 0.001). In Group 1, Ct levels were significantly correlated with creatinine (P &amp;lt; 0.001). In Group 2, median Ct was 3.7 ng\/L (IQR: 1.0\u20137.0 ng\/L), 25 patients (18.5%) had Ct levels &amp;gt;10 ng\/L, and Ct levels were not associated with renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ct levels may be mildly elevated in advanced CKD; until stage 3, the increase is negligible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-26-0021","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:57:23Z","timestamp":1780937843000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":0,"title":["Hypercalcitoninemia in chronic kidney disease: an old issue, a new perspective?"],"prefix":"10.1530","volume":"15","author":[{"given":"Ilaria","family":"Piva","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6946-9673","authenticated-orcid":true,"given":"Simona","family":"Censi","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Favotto","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Clausi","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiammetta","family":"Battheu","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Messina","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Cortese","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Katiana","family":"Martino","sequence":"additional","affiliation":[{"name":"1"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Federica","family":"Stefanelli","sequence":"additional","affiliation":[{"name":"1"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[{"name":"1"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nalesso","sequence":"additional","affiliation":[{"name":"1"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8001","authenticated-orcid":true,"given":"Caterina","family":"Mian","sequence":"additional","affiliation":[{"name":"1"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026072110071776500_bib1","article-title":"Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules","volume":"3","author":"Verbeek","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026072110071776500_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2006-1590","article-title":"Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules","volume":"92","author":"Costante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072110071776500_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"2026072110071776500_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1590\/S1807-59322009000700015","article-title":"Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma","volume":"64","author":"Toledo","year":"2009","journal-title":"Clinics"},{"key":"2026072110071776500_bib5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/EJE-07-0566","article-title":"Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking","volume":"157","author":"d\u2019Herbomez","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2026072110071776500_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1530\/ERC-12-0013","article-title":"Interpretation of serum calcitonin in patients with chronic autoimmune thyroiditis","volume":"19","author":"Grani","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2026072110071776500_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40618-023-02152-x","article-title":"Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia","volume":"47","author":"Censi","year":"2024","journal-title":"J Endocrinological Invest"},{"key":"2026072110071776500_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1507\/endocrj.EJ19-0610","article-title":"Calcitonin levels by ECLIA correlate well with RIA values in higher range but are affected by sex, TgAb, and renal function in lower range","volume":"67","author":"Ito","year":"2020","journal-title":"Endocr J"},{"key":"2026072110071776500_bib9","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1515\/cclm-2015-1161","article-title":"Calcitonin measurement and immunoassay interference: a case report and literature review","volume":"54","author":"Censi","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2026072110071776500_bib10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1210\/jc.2015-3137","article-title":"Macrocalcitonin is a novel pitfall in the routine of serum calcitonin immunoassay","volume":"101","author":"Alves","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072110071776500_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.0954-6820.1979.tb06114.x","article-title":"Serum calcitonin in patients with chronic renal disease","volume":"205","author":"Nielsen","year":"1979","journal-title":"Acta Med Scand"},{"key":"2026072110071776500_bib12","first-page":"39","article-title":"Normal calcitonin response to pentagastrin stimulation in patients with chronic renal failure","volume":"129","author":"Escalada","year":"1993","journal-title":"Acta Endocrinol"},{"key":"2026072110071776500_bib13","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/ndt\/10.12.2259","article-title":"The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function","volume":"10","author":"Messa","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"2026072110071776500_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/thy.1998.8.265","article-title":"Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin","volume":"8","author":"Lissak","year":"1998","journal-title":"Thyroid"},{"key":"2026072110071776500_bib15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/thy.1999.9.943","article-title":"Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma","volume":"9","author":"Kotzmann","year":"1999","journal-title":"Thyroid"},{"key":"2026072110071776500_bib16","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/j.1600-6143.2005.00908.x","article-title":"Reversibility of \u201csecondary hypercalcitoninemia\u201d after kidney transplantation","volume":"5","author":"Borchhardt","year":"2005","journal-title":"Am J Transplant"},{"key":"2026072110071776500_bib17","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/sj.ki.5001888","article-title":"Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia","volume":"70","author":"Borchhardt","year":"2006","journal-title":"Kidney Int"},{"key":"2026072110071776500_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-019-4479-6","article-title":"Calcitonin concentrations in patients with chronic kidney disease on hemodialysis in reference to parathyroidectomy","volume":"12","author":"Sabia","year":"2019","journal-title":"BMC Res Notes"},{"key":"2026072110071776500_bib19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5414\/CNP71538","article-title":"Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation","volume":"71","author":"Akan","year":"2009","journal-title":"Clin Nephrol"},{"key":"2026072110071776500_bib20","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026072110071776500_bib21","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication \u2013 worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"key":"2026072110071776500_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026072110071776500_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.0954-6820.1979.tb06115.x","article-title":"Serum calcitonin after renal transplantation","volume":"205","author":"Nielsen","year":"1979","journal-title":"Acta Med Scand"},{"key":"2026072110071776500_bib24","first-page":"123","article-title":"Enhanced calcitonin release in chronic renal failure depending on the absence of severe secondary hyperparathyroidism","volume":"31","author":"Mulder","year":"1982","journal-title":"Nephron"},{"key":"2026072110071776500_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.0.1320075","article-title":"Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis","volume":"132","author":"Niccoli","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2026072110071776500_bib26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40618-020-01356-9","article-title":"Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment","volume":"44","author":"Fugazzola","year":"2021","journal-title":"J Endocrinological Invest"},{"key":"2026072110071776500_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23065","article-title":"Elevated serum procalcitonin level in patients with chronic kidney disease without infection: a case-control study","volume":"34","author":"Wu","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"2026072110071776500_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/cen.15287","article-title":"Combining procalcitonin and calcitonin for the diagnosis of medullary thyroid cancer: a two-step approach","volume":"103","author":"Clausi","year":"2025","journal-title":"Clin Endocrinol"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/3\/ETJ-26-0021.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/3\/ETJ-26-0021.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0021\/520064\/etj-26-0021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0021\/520064\/etj-26-0021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:07:25Z","timestamp":1784642845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/3\/ETJ260021\/77599\/Hypercalcitoninemia-in-chronic-kidney-disease-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-26-0021","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"ETJ260021"}}